T601 (recombinant oncolytic vaccinia virus)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for T601 (recombinant oncolytic vaccinia virus), covering 2020-12-07 to 2020-12-07. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors [Phase 1, Phase 2]